TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Micra Transcatheter Pacing Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who have a Class I or II indication for implantation of a single chamber ventricular pacemaker according to ACC/AHA/HRS 2008 guidelines and any national guidelines~* Subjects who are able and willing to undergo the study requirements and are expected to be geographically stable for the duration of the follow-up.~* Subjects who are at least 18 years of age (or older, if required by local law).~Exclusion Criteria:~* Subjects who are entirely pacemaker dependent (escape rhythm \<30 bpm). (Please note: Subjects who are entirely pacemaker dependent (escape rhythm \<30 bpm) can now be included in the study. Medtronic notified all sites on July 23, 2014 that the restriction against pacemaker dependent subjects was lifted, following review of the Early Performance Assessment.)~* Subject has an existing or prior pacemaker, ICD or CRT device implant.~* Subject has unstable angina pectoris or has had an acute myocardial infarction (AMI) in the 30 days prior to eligibility assessment.~* Subjects with current implantation of neurostimulator or any other chronically implanted device which uses current in the body. Note that a temporary pacing wire is allowed.~* Subjects with a mechanical tricuspid valve, implanted vena cava filter, or left ventricular assist device (LVAD).~* Subjects who are morbidly obese and physician believes telemetry communication of ≤5 inches (12.7 cm) could not be obtained with programmer head.~* Subjects whose femoral venous anatomy is unable to accommodate a 23 French introducer sheath or implant on the right side of the heart (for example, due to obstructions or severe tortuosity) in the opinion of the implanter.~* Subjects who are considered as unable to tolerate an urgent sternotomy~* Subjects with a known intolerance to Nickel-Titanium (Nitinol) Alloy.~* Subjects for whom a single dose of 1.0mg dexamethasone acetate may be contraindicated.~* Subjects with a life expectancy of less than 12- months.~* Subjects who are currently enrolled or planning to participate in a potentially confounding drug or device trial during the course of this study. Coenrollment in concurrent trials is only allowed when document pre-approval is obtained from the Medtronic study manager.~* Pregnant women, or women of child bearing potential and who are not on a reliable form of birth control.~* Subjects with exclusion criteria required by local law (e.g. age, breast feeding, etc.).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Micra Pacemaker Implant (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study of the ACRYSOF® IQ Extended Depth of Focus Intraocular Lens (IOL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Best Corrected Distance Visual Acuity (BCDVA) of 0.3 logarithm of the minimum angle of resolution (logMAR) (20/40 Snellen) or worse either with or without a glare source present (e.g., Brightness Acuity Tester)~* Preoperative regular astigmatism of \< 1.0 D in both eyes~* Clear intraocular media other than cataract~* Diagnosed with cataract in both eyes~* Planned cataract removal by routine small incision surgery~* Calculated lens power between 18.0 and 25.0 diopter (D) \[when targeted for emmetropia (0.0 D)\]~* Willing and able to complete all required postoperative visits~* Able to comprehend and sign an ethics committee-approved statement of informed consent~* Potential postoperative BCDVA of 0.2 logMAR (20/32 Snellen) or better in each eye based on Investigator's medical opinion.~Exclusion Criteria:~* History of eye pathology and/or inflammation, as specified in the protocol~* Clinically significant/severe ocular surface disease that would affect study measurements based on Investigator expert medical opinion~* History of previous intraocular or corneal surgery~* Pregnant/lactating or has another condition with associated fluctuation of hormones that could lead to refractive changes~* Taking systemic medications that in the Investigator's best medical judgment may confound the outcome or increase the risk to the subject.

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DFT015 (Type: EXPERIMENTAL): ACRYSOF® IQ Extended Depth of Focus Intraocular lens (IOL), bilateral implantation
- SN60WF (Type: ACTIVE_COMPARATOR): ACRYSOF® IQ Monofocal IOL, bilateral implantation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Rifaximin in Minimal Hepatic Encephalopathy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-65 years~* cirrhosis diagnosed by clinical or biopsy grounds~* Minimal hepatic encephalopathy defined by impaired performance on at least 2 of the following: number connection tests A/B, digit symbol and block design tests (NCT-A, NCT-B, DST and BDT) compared to age and education-matched controls.~* No contraindications to MRI~* TIPS (transjugular intra-hepatic porto-systemic shunt) procedure or elective surgery planned within the next 8 weeks~Exclusion Criteria:~* Current therapy with lactulose, rifaximin or other treatment for hepatic encephalopathy.~* Prior episodes of overt HE~* MMSE \<25~* TIPS placement~* Unable to give informed consent.~* Contra-indications to MRI

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Rifaximin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Effectiveness Between Microprocessor Knees and Non-Microprocessor Knees

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Unilateral transfemoral amputee~* Medicare Functional Classification Level K2 or K3~* Currently using NMPK prosthesis~* No current residual limb problems, such as skin breakdown~* Able to ambulate without a gait aid~Exclusion Criteria:~* Previous stroke or other neuromuscular complications currently affecting gait~* Currently undergoing dialysis treatments~* Amputation of the contralateral limb~* Poor fit of current NMPK prosthesis

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prosthetic knee joints (Type: EXPERIMENTAL): Each subject will be tested using their current Non-Microprocessor Knee (NMPK) , fit and tested with a Microprocessor Knee (MPK), and then tested again with their NMPK, e.g. A-B-A design.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Testosterone Treatment on Clitoral Arteries' Hemodynamic Parameters.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* being heterosexual.~Exclusion Criteria:~* history of drug or alcohol abuse~* a diagnosis of uncontrolled or unstable mental or organic disease.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hypoactive Sexual Desire Disorder (Type: None): Women with Hypoactive Sexual Desire Disorder (HSDD, n=23)
- Moderate to severe VVA (Type: None): Women with dyspareunia due to moderate to severe vulvovaginal atrophy (VVA) (n=12)
- Mild to moderate VVA (Type: None): Women with dyspareunia due to mild to moderate VVA (n=37)
- HSDD + VVA (Type: None): Women with HSDD reporting also significant dyspareunia due to moderate to severe VVA (n=9).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histopathological proven prostate adenocarcinoma.~2. Rising prostate specific antigen (PSA) after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy).~   1. Post radical prostatectomy (RP) - according to American Urological Association (AUA) recommendation criteria: PSA greater than 0.2 ng/mL measured more than 6 weeks after RP and confirmatory persistent PSA greater than 0.2 ng/mL.~  2. Post-radiation therapy - according to ASTRO-Phoenix consensus definition: Nadir + greater than or equal to 2 ng/mL rise in PSA.~3. Karnofsky performance status of ≥ 50.~4. Age ≥ 18.~5. Ability to understand a written informed consent document, and the willingness to sign it.~Exclusion Criteria:~1. Current investigational therapy for prostate cancer.~2. Unable to lie flat, still or tolerate a PET/CT scan.~3. Prior history of a malignancy within the last 2 years, except skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized, and except superficial bladder cancer.~4. Prisoner.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patient participants (Type: EXPERIMENTAL): PET/CT imaging

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optive Brand For Day And Night Dry Eye Management

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* OSDI score of ≥ 23~* Ocular comfort at waking \<65 on 100-point scale~* Conjunctival staining Grade ≥ 2 (scale 0 to 4) in at least one eye~* Use of eyedrops for the relief of dry eye symptoms for at least one month~* Best corrected visual acuity in each eye of at least 20/25~* Have normal eyes with the exception of the need for visual correction; subjects must be willing to cease contact lens wear for the duration of the study~* Be willing and able to adhere to the instructions set in the clinical protocol and maintain the appointment schedule~Exclusion Criteria:~* Use of Benzalkonium Chloride (BAK) preserved eyedrops in the last month~* Use of Optive brand eyedrops in the last month~* Monocular participants (only one eye with functional vision).~* Contact lens wear during the study~* History of herpetic keratitis, ocular surgery or irregular cornea;~* Known pregnancy or lactation during the study period~* Participation in any clinical trial within 30 days of the enrollment visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Optive® Fusion + Optive® Gel Drop (Type: EXPERIMENTAL): Optive® Fusion eyedrop will be used as needed up to four times a day but at least twice a day. The eyedrop will be used once in the evening; the gel drop being instilled any time during the last hour prior to sleep. The treatment regimen will be used for one month.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Premedication on Sevoflurane Induction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA physical status I-II~* Minor elective surgery~* General anesthesia~Exclusion Criteria:~* Gastroesophageal reflux~* Exhibited a body mass index \> 32 kg/m2~* Took sedative or opioid drugs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- FM (Type: ACTIVE_COMPARATOR): Premedication consisting of fentanyl 0.6 ug/kg and midazolam 9 ug/kg (FM), five minutes before tidal volume sevoflurane 8% induction with 6 L/min O2.
- NaCl (Type: PLACEBO_COMPARATOR): A 2.5 ml NaCL placebo (NaCl) IV, five minutes before tidal volume sevoflurane 8% induction with 6 L/min O2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Anti-VEGFR2 AK109 in Subjects With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have signed written informed consent form voluntarily.~* Histologically or cytologically documented advanced solid tumor that is refractory/relapsed/intolerant to standard therapies, or for which no effective standard therapy is available, or subject refuses standard therapy.~* Have radiologically measurable disease based on RECIST 1.1~* ECOG of 0 or 1.~* Estimated life expectancy of ≥3 months.~* Adequate organ function.~* Have agreed to take effective contraception from the date of signing the informed consent form until 120 days after the last administration.~Exclusion Criteria:~* have been diagnosed other advanced tumors within 2 years before the first use of the study drug, except for the cured localized tumors.~* with active central nervous system metastasis, cancerous meningitis, or spinal cord compression.~* Prior use of any anti-VEGF or anti-VEGFR antibodies.~* Receipt of anti-tumor treatment, other study drug, major surgery, or serious infection within 4 weeks prior to C1D1 (Cycle 1 Day1, the first dose of study drug).~* Have received central venous catheterization within 7 days prior to C1D1.~* Severe or uncontrolled cardiovascular and cerebrovascular diseases.~* Uncontrolled hypertension.~* have a high risk of bleeding.~* Uncontrolled gastrointestinal diseases.~* Uncontrolled pleural/pericardial or peritoneal effusion.~* Have occurred any thromboembolic event, non-gastrointestinal fistula or female genital tract fistula within 6 monthsprior to C1D1.~* With cirrhosis of Child-Pugh B or C.~* Active or unstable viral hepatitis; or active tuberculosis.~* Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.~* received live vaccines prior 30 days within the first dose.~* take apart in other clinical studies at the same time.~* known to be allergic to any component of AK109, other monoclonal antibodies or any therapeutic protein.~* mental illness, drug abuse, or alcohol dependence that may affect compliance with the test requirements.~* Any treatment risk or condition that interferes with the study by the investigator judged.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AK109 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Point-of-care Health Literacy and Activation Information to Improve Diabetes Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Veterans receiving primary care at VA study sites who are enrolled in the panels of participating primary care teams~* Veterans with ICD-9-CM and/or ICD-10 codes indicating a diagnosis of diabetes~* Veterans with an average HbA1c level \> 8% in the prior 6 months~Exclusion Criteria:~The investigators will exclude Veterans with the following clinical conditions that would render participation in a group clinic inappropriate:~* metastatic cancer or receiving hospice care~* limited life expectancy~* clinician recommendations to not titrate therapy due to prior history of significant hypoglycemic events~* age \<18 years~* active bipolar or psychotic disorder~The investigators will also exclude Veterans, who at the time of screening:~* cannot attend monthly group clinic sessions due to transportation or availability barriers~* have significant cognitive impairment~* have active substance-abuse disorders~* are not comfortable discussing their health and health care in a peer-group setting Patients will be secondarily excluded if their HbA1C level falls below 7.5% at baseline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: Empowering Patients in Chronic Care (EPIC) (Type: EXPERIMENTAL): Patients in the intervention arm will receive the Empowering Patients in Chronic Care group training sessions consisting of 6 one-hour group sessions occurring over a 6-month period. Group sessions will consist of behavioral coaching focused on diabetes management. Following each group-session, patients enrolled in the intervention arm will meet with a designated member of their primary care team to personalize diabetes goals and action plans.
- Arm 2: Enhanced Usual Care (EUC) (Type: ACTIVE_COMPARATOR): The Enhanced Usual Care (EUC) arm will serve as a concurrent control group to compare to the intervention arm of the study. Patients randomized to EUC will be referred to the PACT RN Care Manager for diabetes management, and will also receive a packet of educational materials regarding diabetes management, including a letter delineating the diabetes management resources available at their facility.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older at time of consent.~* Active, moderate to severe chronic plaque psoriasis defined by the following criteria: Clinically stable, plaque psoriasis involving greater than or equal to 10% body surface area (BSA) or PASI greater than or equal to 10.~* In the opinion of the investigator, failure, intolerance, contraindication or not a candidate for the following: Methotrexate (MTX), cyclosporine and psoralen plus ultraviolet A radiation (PUVA) therapy.~Exclusion Criteria:~* Evidence of skin conditions (e.g., eczema) other than psoriasis that would interfere with evaluations of the effect of study medication on psoriasis.~* Rheumatologic disease such as rheumatoid arthritis, systemic lupus erythematous, systemic vasculitis, scleroderma and polymyositis, or associated syndromes.~* Active or recent (within 2 years) tuberculosis (TB) infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): A
- Group B (Type: EXPERIMENTAL): B

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Brief Intervention for Justice-Involved Substance Users

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* In Monroe County Pretrial Services Program~Exclusion Criteria:~* none

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brief Motivational Intervention (BMI) (Type: EXPERIMENTAL): None
- Standard Care (SC) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete